Influenza 2010-2011: Lessons from the 2009 pandemic

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 11, 2010, Pages 812-820

  Ison, Michael G ^a,b   Lee, Nelson ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; ANTIVIRUS AGENT; INFLUENZA VACCINE;

DIAGNOSTIC TEST; DRUG RESISTANCE; EPIDEMIC; HEALTH; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; REVIEW; RISK FACTOR; SEASON;

ADAMANTANE; ANTIVIRAL AGENTS; DIAGNOSTIC TESTS, ROUTINE; DISEASE OUTBREAKS; DRUG RESISTANCE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; RISK FACTORS; SEASONS; WORLD HEALTH;

EID: 78249237571     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.10135     Document Type: Review

References (92)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-1340.
2. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-1062.
3. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178:53-60.
4. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza; Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-1719.
5. Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010; 304:1091-1098.
6. Fiore AE, Uyeki TM, Broder K, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
7. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-689.
8. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:400-402.
9. Khan K, Arino J, Hu W, et al. Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med 2009; 361:212- 214.
10. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
11. Hayden FG, Palese P. Influenza virus. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 2nd ed. Washington, DC: ASM Press; 2002:891-920.
12. Smith D. Assessing antigenic drift for vaccine development. Presented Sept 7, 2010 at the Options for the Control of Influenza VII in Hong Kong SAR, China.
13. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009; 360:2616-2625.
14. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-1952.
15. National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1-8.
16. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460:1021-1025.
17. Chen MI, Lee VJ, Lim WY, et al. 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 2010; 303:1383-1391.
18. Lee VJ, Yap J, Tay JK, et al. Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009. BMC Infect Dis 2010; 10:164.
19. White LF, Wallinga J, Finelli L, et al. Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza Other Respi Viruses 2009; 3:267-276.
20. Ross T, Zimmer S, Burke D, et al. Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza. PLoS Curr 2010: RRN1148.
21. Hayward A. Surveilance during the pandemic: lessons learned. Presented Sept 5, 2010 at the Options for the Control of Influenza VII in Hong Kong SAR, China.
22. Campbell A, Rodin R, Kropp R, et al. Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010; 182:349-355.
23. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182:257-264.
24. Siston AM, Rasmussen SA, Honein MA, et al; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-1525.
25. Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010; 50:1498-1504.
26. Sugaya N, Mitamura K, Shinjho M, Yamada M, Takahashi T. Early treatment with neuraminidase inhibitors and hospitalized children with pandemic A (H1N1) influenza infection in Japan. Abstract O-824. Presented Sept. 2010 at the Options for the Control of Influenza VII in Hong Kong SAR, China.
27. Tang JW, Tambyah PA, Lai FY, et al. Differing symptom patterns in early pandemic vs seasonal influenza infections. Arch Intern Med 2010; 170:861-867.
28. Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:2175-2184.
29. Lee N, Chan PKS, Wong CK, Wong KT, Choi KW, Joynt GM. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2010; in press.
30. Shiley KT, Nadolski G, Mickus T, Fishman NO, Lautenbach E. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol 2010; 31:676-682.
31. Hassan K, McGeer A, Green KA, et al. Antiviral therapy improves outcome of influenza infections in patients requiring admission to intensive care. Abstract V-537. Presented in 2009 at the 49th ICAAC. San Francisco, CA.
32. Kuster SP, Drews S, Green K, et al. Epidemiology of influenza-associated hospitalization in adults, Toronto, 2007/8. Eur J Clin Microbiol Infect Dis 2010; 29:835-843.
33. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-1575.
34. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 38(suppl 4):e91-e97.
35. Thompson WW, Moore MR, Weintraub E, et al. Estimating influenzaassociated deaths in the United States. Am J Public Health 2009; 99(suppl 2):S225-S230.
36. Babcock HM, Merz LR, Dubberke ER, Fraser VJ. Case-control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29:921-926.
37. McGeer AJ. Diagnostic testing or empirical therapy for patients hospitalized with suspected influenza: what to do? Clin Infect Dis 2009; 48(suppl 1):S14-S19.
38. Harper SA, Bradley JS, Englund JA, et al; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-1032.
39. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 361:728-729.
40. Ganzenmueller T, Kluba J, Hilfrich B, et al. Comparison of the performance of direct fluorescent antibody staining, a point-of-care rapid antigen test and virus isolation with that of RT-PCR for the detection of novel 2009 influenza A (H1N1) virus in respiratory specimens. J Med Microbiol 2010; 59:713-717.
41. Ison MG, Rosenberg ES. RNA respiratory viruses. In: Hayden RT, Carroll KC, Tang YW, Wolk DM, eds. Diagnostic Microbiology of the Immunocompromised Host. Washington, DC: ASM Press; 2009:141-160.
42. Kumar A, Zarychanski R, Pinto R, et al; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872-1879.
43. Ngaosuwankul N, Noisumdaeng P, Komolsiri P, et al. Influenza A viral loads in respiratory samples collected from patients infected with pandemic H1N1, seasonal H1N1 and H3N2 viruses. Virol J 2010; 7:75.
44. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850-859.
45. Centers for Disease Control and Prevention (CDC). Oseltamivirresistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:893-896.
46. Kumar D, Michaels MG, Morris MI, et al; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-526.
47. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373.
48. Hayden FG, Aoki FY. Amantadine, rimantadine, and related agents. In: Yu VL, Merigan TCJ, Barriere SL, eds. Antimicrobial Therapy and Vaccines. 1st ed. Baltimore, MD: Williams & Wilkins; 1999:1344-1365.
49. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009; 361:1713-1714.
50. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357-363.
51. Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.
52. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887-894.
53. Cheng AC, Dwyer DE, Kotsimbos AT, et al; Australasian Society for Infectious Diseases and the Thoracic Society of Australia and New Zealand. Summary of the Australasian Society for Infectious Diseases and the Thoracic Society of Australia and New Zealand guidelines: treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents. Med J Aust 2009; 191:142- 145.
54. Kumar D, Morris MI, Kotton CN, et al; AST Infectious Diseases Community of Practice and Transplant Infectious Diseases Section of TTS. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10:18-25.
55. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother 2010; 65(suppl 2):ii11-ii24.
56. Ison MG. Influenza in hospitalized adults: gaining insight into a significant problem. J Infect Dis 2009; 200:485-488.
57. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510-515.
58. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-1662.
59. Li CC, Wang L, Eng HL, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 2010; 16:1265-1272.
60. Ison MG, Gnann JW Jr, Nagy-Agren S, et al; NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190.
61. Ison MG, McGeer AJ, Hui DS, et al. Safety and efficacy of multipleday treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. Presented in 2009 at the XI International Symposium on Respiratory Viral Infections. Bangkok, Thailand.
62. Yates PJ, Man CY, Zhao H, et al. Interim virological analysis of a prospective single arm phase II study of intravenous zanamivir for the treatment of hospitalized patients with influenza A/H1N1 2009 infection. Abstract P-160. Presented at the Sept. 2010 Options for the Control of Influenza VII. Hong Kong, SAR, China.
63. South East Asia Infectious Disease Clinical Research Network (ASEAICRN) SEA001 Protocol Team. SEA001: High-dose vs standarddose oseltamivir for the treatment of severe influenza. Abstract P-205. Presented at the Sept. 2010 Options for the Control of Influenza VII. Hong Kong, SAR, China.
64. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361:1935-1944.
65. ANZIC Influenza Investigators; Webb SA, Pettilä V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925-1934.
66. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501-508.
67. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009; 4:e6051.
68. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:100-105.
69. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435-1441.
70. Witkop CT, Duffy MR, Macias EA, et al. Novel Influenza A (H1N1) outbreak at the U.S. Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010; 38:121-126.
71. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-969.
72. World Health Organization. Clinical management of human infection with pandemic (H1N1) 2009: revised guidance. http://www. who.int/csr/resources/publications/swineflu/clinical_management/en/index .html. Accessed October 7, 2010.
73. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010; 115:1331-1342.
74. Ison MG. Anti-influenza therapy: the emerging challenge of resistance. Therapy 2009; 6:883-891.
75. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672.
76. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009; 301: 1042-1046.
77. Speers DJ, Williams SH, Pinder M, Moody HR, Hurt AC, Smith DW. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010; 192:166-168.
78. Baz M, Abed Y, Nehmé B, Boivin G. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. Antimicrob Agents Chemother 2009; 53:791-793.
79. Dharan NJ, Gubareva LV, Meyer JJ, et al; Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
80. Stephenson I, Hayden F, Osterhaus A, et al. Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. Vaccine 2010; 28:3875-3882.
81. Anikeeva O, Braunack-Mayer A, Rogers W. Requiring influenza vaccination for health care workers. Am J Public Health 2009; 99:24-29.
82. Palmore TN, Vandersluis JP, Morris J, et al. A successful mandatory influenza vaccination campaign using an innovative electronic tracking system. Infect Control Hosp Epidemiol 2009; 30:1137-1142.
83. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory influenza vaccination of healthcare workers: a 5-year study. Infect Control Hosp Epidemiol 2010; 31:881-888.
84. Talbot TR, Schaffner W. On being the first: Virginia Mason Medical Center and mandatory influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 2010; 31:889-892.
85. Talbot TR, Babcock H, Caplan AL, et al. Revised SHEA position paper: influenza vaccination of healthcare personnel. Infect Control Hosp Epidemiol 2010; 31:987-995.
86. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA 2009; 302:1865-1871.
87. Tellier R. Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interface 2009; 6(suppl 6):S783-S790.
88. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53:1-36.
89. Yunoki M, Kubota-Koketsu R, Urayama T, et al. Significant neutralizing activity of human immunoglobulin preparations against pandemic 2009 H1N1. Br J Haematol 2010; 148:953-955.
90. Hong DK, Tremoulet AH, Burns JC, Lewis DB. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 2010; Epub ahead of print.
91. McAuley JL, Chipuk JE, Boyd KL, Van De Velde N, Green DR, McCullers JA. PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog 2010; 6:e1001014.
92. Anderson T, Capua I, Dauphin G, et al. FAO-OIE-WHO Joint Technical Consultation on Avian Influenza at the Human-Animal Interface. Influenza Other Respi Viruses 2010; 4(suppl 1):1-29.